US72942G2030 - Common Stock
PLURI INC
NASDAQ:PLUR (5/7/2024, 7:17:02 PM)
5.89
+0.29 (+5.18%)
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
PLURI INC
Matam Park Building 5
Haifa
P: 972747108600
Employees: 123
Website: https://pluri-biotech.com/
Placental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are particularly suitable for the treatment of solid...
Pluri just reported results for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pluri (NASDAQ:PLUR) just reported results for the fourth quarter of 2023.Pluri ...
Pluri’s business verticals leverage Company’s world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring...
HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (
International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee...
Here you can normally see the latest stock twits on PLUR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: